Cumberland Pharmaceuticals Inc.: accounts_receivable
| Value | {"amount": 7843917, "concept": "us-gaap:AccountsReceivableNetCurrent", "currency": "USD"} |
|---|---|
| Period | (as of 2019-12-31) |
| Status | superseded |
| Entity | Cumberland Pharmaceuticals Inc. |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T10:49:03.146245+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/cab9ca89-1c11-4b12-8d3c-11807e83fab2
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0001628280-20-008312Retrieved: 2026-08-19T10:49:03.146245+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0001087294/accounts-receivable/2019-12-31 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/cab9ca89-1c11-4b12-8d3c-11807e83fab2
History
- supersedes {"amount": 9781463, "concept": "us-gaap:AccountsReceivableNetCurrent", "currency": "USD"} (evidence 0001628280-20-003880)